Larimar director granted 55,150 stock options

Larimar Therapeutics director Jeffrey W. Sherman received a grant of 55,150 stock options for common stock.

Rhea-AI Filing Summary

Larimar Therapeutics director Jeffrey W. Sherman received a grant of 55,150 stock options for common stock. These options carry an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued board service. This is a compensation-related award rather than an open-market trade, and no common shares were bought or sold in this filing.

Insider Trade Summary

Grant/Award: 55,150 shares

Grant/Award 1 txn

Insider SHERMAN JEFFREY W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,150	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 55,150 contracts (Direct)

Footnotes (1)

1. F1. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Key Figures

Stock options granted: 55,150 options Exercise price: $3.33 per share Expiration date: May 19, 2036 +1 more

4 metrics

Stock options granted 55,150 options Grant to director Jeffrey W. Sherman

Exercise price $3.33 per share Exercise price for the stock option grant

Expiration date May 19, 2036 Option term end for the grant

Vesting date trigger Earlier of May 19, 2027 or next annual meeting Subject to continued board service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Board of Directors

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)" for 55,150 shares."

exercise price financial

"The options have a conversion or exercise price of $3.33 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option award carries an expiration date of May 19, 2036."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Board of Directors financial

"Vesting is subject to the Reporting Person's continued service on the Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Larimar Therapeutics (LRMR) report for Jeffrey W. Sherman?

Larimar Therapeutics reported that director Jeffrey W. Sherman received a grant of 55,150 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as equity-based compensation rather than an open-market stock purchase or sale.

What are the key terms of Jeffrey W. Sherman’s Larimar (LRMR) stock option grant?

Sherman’s grant covers 55,150 stock options with an exercise price of $3.33 per share and an expiration date of May 19, 2036. The options relate to common stock and represent potential future ownership if exercised after vesting conditions are met.

When do Jeffrey W. Sherman’s Larimar (LRMR) stock options vest?

The options vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting. Vesting is contingent on Sherman’s continued service on the Board of Directors through that vesting date, aligning the award with ongoing board tenure.

Did Jeffrey W. Sherman buy or sell Larimar Therapeutics (LRMR) shares in this Form 4?

No, this Form 4 reports a grant of stock options, not an open-market share purchase or sale. The transaction is classified as a derivative award, providing rights to acquire shares in the future rather than reflecting an immediate change in common stock ownership.

How many Larimar (LRMR) options does Jeffrey W. Sherman hold after this grant?

After this grant, Sherman is reported as holding 55,150 stock options directly. These options are all from this award and give him the right to purchase an equal number of common shares at the stated $3.33 exercise price if he chooses to exercise them later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERMAN JEFFREY W

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PENNSYLVANIA 19004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.33	05/19/2026		A		55,150		(1)	05/19/2036	Common Stock	55,150	$0	55,150	D

Explanation of Responses:

1. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

	/s/ Jennifer Johansson, Attorney-in-fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)